Chinese investors acquired SciClone Pharmaceuticals for $605 million
A consortium of Chinese investment firms have acquired stake in SciClone, a California Pharmaceutical firm, for $605 million.
Headquartered in Foster City California and listed on NASDAQ, SciClone is a revenue-generating pharmaceutical company with a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. (The buyer consortium consists of entities affiliated with GL Capital Management founded by Jeffrey Li, Bank of China Group Investment, CDH Investments, Ascendent Capital Partners, and Boying Investments of Weihang Zhu).
CDH Investments is listed in the Chinese Private Equity and Venture Capital Directory with the code OR41.
More details follows:
Investors Directory 2022
